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In theory, the use of antisense oligodeoxynucleotides provides a method to inhibit the intracellular expression of arty given targeted gene specifically. Such inhibition can be accomplished because of the exquisite specificity of the WatsonCrick base-pair interactions that result in the formation of a messenger RNA (mRNA)-DNA hybrid structure. Because of this specificity, it has been estimated that an oligodeoxynucleotide of 15-17 residues in length may be unique in the entire human genome.
The power and elegance of this approach has been demonstrated numerous times, both in tissue culture and in vivo, and oligodeoxynucleotides have recently entered clinical trials as therapeutic antineoplastic and anti-HIV agents. One striking demonstration of the ability of antisense oligodeoxyrtucleotide technology to produce useful data was given by Methia et al. (7) . They demonstrated, via a targeted antisense approach, that the proto-oncogene c-mpl was the cell surface receptor for a thrombopoietic substance. They then used this information to isolate, by affinity chromatography, and then clone, sequence, and produce thrombopoietin. Recently, thrombopoietin has entered clinical trials. Furthermore, since several tens of thousands of human genes will be sequenced over the next decade, it bcomes essential to have a rapid, high through-put, relatively inexpensive method to determine their cellular functions. Antisense oligodeoxynucleotide technology can, in theory, provide such a method.
However, phosphodiester oligodeoxynucleotides (normal DNA) have somewhat limited utility as antisense reagents because they undergo nuclease digestion, primarily by 3'-5' exonucleases. To vitiate this problem, phosphorothioate oligodeoxynucleotides were synthesized by Stec et al. (2) . These compounds have a sulfur for oxygen replacement at a nonbridging position at each phosphorus atom in their phosphodiester backbones. Phosphorothioates are nuclease resistant (although not nuclease proof), and they retain the aqueous solubility of the parental phosphodiester oligodeoxynucleotides. They also hybridize well to target mRNAs, and they can elicit the activity of RNase H, an enzyme found predominantly in the cell nucleus that cleaves the mRNA strand of an mRNA-DNA duplex. RNase H activity has been proven to be a major contributor to the net antisense activity in Xenopus oocytes and is also believed to be so in mammalian cells, although the extent to which this is the case is not completely clear. However, phosphorothioate oligodeoxynucleotides have an additional property that complicates interpretation of experimental data obtained from their use, i.e., they bind avidly to proteins, particularly (as far as has been defined) to heparin-binding proteins (3). In general, the dissociation constant (Kj) of a phosphorothioate oligodeoxynucleotide/protein complex is approximately two to three orders of magnitude lower than that found for the corresponding phosphodiester oligodeoxynucleotide/protein complex. This finding may be a reflection of the fact that, at least in some cases, the rate of dissociation of a phosphorothioate oligodeoxynucleotide from protein is extremely slow. Examples of heparin-binding proteins now known to bind directly to phosphorothioate oligodeoxynucleotides include basic fibroblast growth factor (bFGF), acidic fibroblast growth factor, plateletderived growth factor, vascular endothelial cell growth factor, protein kinase C (multiple isoforms), CD4, and gpl20 (3,4). This protein binding appears to be dependent on the length of the oligomer and, to some extent, on its sequence as well. For example, phosphorothioate oligodeoxynucleotides that contain the G-quartet motif (four contiguous guanosine residues) possess augmented nonsequence specificity, perhaps due to their increased ability to bind to proteins (e.g., to bFGF) (3).
How do the complexities of data interpretation when phosphorothioate oligodeoxynucleotides are used as antisense reagents in tissue culture experiments impact on the study by Leonetti et al. (5) reported in this issue of the Journal? First, there can be little question that the 15-mer antisense c-myc phosphorothioate oligodeoxynucleotide employed by these investigators is highly active biologically and that this activity is substantially greater than that found for the control oligodeoxynucleotides. The proliferation of M14, JR8, and PLF2 melanoma cells in tissue culture was dramatically slowed by treatment with the antisense c-myc, but not the control, oligomers. Furthermore, the antisense, but not control, oligomers, which included a control containing the G-quartet motif, induced apoptosis in a large proportion of the treated cells. Using primary NG melanoma cells in culture, treatment with the oligomers was correlated with a decrease in the number of cells in S phase, a decrease in cellular proliferation, and, most significantly, a decrease in c-Myc protein levels. (Demonstration of a decrease in the translation product of the specific target mRNA, so critical for the determination of an antisense mechanism, was not provided for the M14, JR8, or PLF2 cells.) In nude mice bearing transplanted tumors, a dose and schedule diminution in tumor weight (80% for alternating doses of 1 and 0.5 mg for 8 consecutive days; P = .0013 versus scrambled oligomer-treated controls) was observed and was correlated with delayed tumor regrowth and an increase in animal survival. In addition, whereas 85% of the NG melanoma cells from the untreated mice were c-Myc positive by fluorescence-activated cell sorter analysis, only about 13% of the cells of the antisensetreated mice were c-Myc positive. About 70% of the NG cells from the antisense-treated mice were found to be apoptotic, whereas none of the control oligomers increased the base-line level of cellular apoptosis. Thus, it must be concluded that the antisense phosphorothioate oligodeoxynucleotide used by Leonetti et al. (5) is a potent inhibitor of the proliferation of NG cells in nude mice.
But does it act through an antisense mechanism? The data presented, although extensive, highly believable, and technically impeccable, raise some interesting questions of interpretation. It is interesting that the phosphorothioate deoxyoligonucleotide used here produces results that appear to be sequence specific. 
be approximately 30 °C (7). This value is significantly below the incubation temperature of the experiments (37 °C) and implies that RNAse H, as it is known to do, might be stabilizing the duplex formed between the target mRNA and the antisense oligodeoxynucleotide. If this is true, then decreased mRNA levels, and even appropriately sized mRNA fragments, should be observed because of RNase-H-mediated cleavage. However, such data have, historically, been exceptionally difficult to obtain.
But how could the results of Leonetti et al. possibly be nonsequence specific? Clearly, it could be reasoned that these investigators have used an adequate number of apppropriate controls. They have even employed a control oligomer in which the Gquartet motif was left intact. A counterargument, however, has been advanced by Maltese et al. (8) , who have noted that the presence of a G-quartet motif alone is insufficient to augment nonsequence specificity, at least in some systems. Rather, it is the presence of the G quartet plus the flanking sequences that is important. By this reasoning, if the G quartet is maintained and the flanking sequences are mutated, the nonsequence-specific properties of the phosphorothioate oligomer may be diminished. Of course, if only the G-quartet motif is altered, diminished nonsequence specificity may result. Unfortunately, the data of Additional problems of data interpretation arise because cMyc is a protein that is involved in the regulation of the cell cycle and whose intracellular levels may be conceivably diminished because of alterations in that cycle. It is just possible that such alterations may be induced in a sequence-selective manner by a highly biologically active phosphorothioate oligodeoxynucleotide at a point "upstream" of the regulation of c-Myc protein levels.
Finally, it has been shown recently (9) that a phosphorothioate oligodeoxynucleotide containing a CpG motif may be highly immunostimulatory. Leonetti et al. (5) have recognized this by noting splenomegaly and axillary and inguinal lymphadenopathy in some treated animals. However, the extent of the immunostimulation for phosphorothioate oligomers of equal length may depend on the location of the CpG motif in the sequence. Only one of Leonetti et al.'s control oligomers contains the CpG motif in the same location as the antisense oligomer, but this control does not contain the G-quartet motif.
But does any of this really matter? If your primary interest is in developing a clinical therapeutic agent, as many biotech firms are, probably not. The Leonetti et al. oligomer is an active antiproliferative, regardless of its mechanism(s) of action, and it is an interesting and valuable lead for further development. However, if you seek specific inhibition of mRNA translation, then mechanism is important and the waters are muddier. In the relatively near future, this situation may improve somewhat by the introduction of newer oligodeoxynucleotide backbones (e.g., phosphoramidates) that are far less avid protein binders than are the phosphorothioates. In addition, chimeric oligomers, for example those that include phosphodiesters and phosphorothioates or other linkages in their backbones, may prove to be active and stable and to have fewer nonsequence-specific properties than the all-phosphorothioates. And none of this discussion rules out the possibility that the all-phosphorothioate oligomers may have a very bright clinical future in their own right. Even though the antisense technology field is more than 10 years old, it is a curious and controversial area whose complexities we are just beginning to fathom.
